Search results
Results from the WOW.Com Content Network
Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker. The company's blockbuster Xarelto drug generated ...
(Reuters) -A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals known as PCBs at a Seattle-area school, but found the company ...
In 2020, Bayer settled most of the then-pending Roundup cases for up to $9.6 billion but failed to get a settlement covering future cases. More than 50,000 claims remain pending.
Individual lawsuits continued to fail because most states had laws shielding blood products from traditional product liability claims. [2] However, discovery was producing damaging documents contending that the companies had collected blood from high-risk donors like homosexuals and prisoners, intensifying informal settlement negotiations. [2]
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Bayer and Johnson & Johnson announce that they have reached a $775 million agreement to settle approximately 25,000 outstanding litigation cases, which claim that their drug Xarelto caused severe and sometimes fatal bleeding episodes. Bayer and Johnson & Johnson had successfully defended the safety of the drug in all six prior cases that went ...
Eliquis brought Bristol Myers about $8.52 billion in U.S. sales last year, while J&J recorded $2.36 billion in Xarelto sales. Eliquis is shared with Pfizer and Xarelto with Bayer, which were not ...
Much of his case was initially dismissed by a trial judge, who agreed with Bayer that his failure-to-warn claims were barred by federal law. The 11th Circuit panel in July 2022 disagreed and ...